GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

RO4998452

Company
Hoffmann-La Roche
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT00682097

    A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.

    Not yet reported Hoffmann-La Roche 55 participants Est. completion 2009-03 3 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00800176

    A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus

    Not yet reported Hoffmann-La Roche 394 participants Est. completion 2009-10-28 67 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT00933972

    A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment

    Not yet reported Hoffmann-La Roche 36 participants Est. completion 2010-09 2 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01044017

    A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes

    Not yet reported Hoffmann-La Roche 22 participants Est. completion 2010-08 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.